Image from Wikipedia.
A Summit News article is explaining an admission from Merck that they are scrapping their COVID vaccines due to the fact that they offer less protection than simply contracting the virus and developing antibodies.
In their statement, the company said their V590 and V591 shots were ‘well tolerated’ by test patients, but they generated an “inferior” immune response in comparison to natural infection. The statement goes on to say that the company will focus on research into therapeutic drugs labeled as MK-7110 and MK-4482, which they say aim to protect patients from an “overactive immune response” to the virus.
[Note: I wouldn’t be surprised if the “MK-7110 and MK-4482” drugs they are developing are simply a variant of the very effective Hydroxychloroquine with Zinc treatment. Merck needs to be able to recoup its losses from not offering a vaccine since it was being given $356 million to do so.]